Eli Lilly and Company
NYSEEli Lilly and Company heads into the back half of September with the short rebuild that dominated last week's note showing its first real signs of fatigue — yet the broader story remains intact. Short interest slipped fractionally on September 15, falling 0.4% on the day to 8.51 million shares, or 0.95% of free float. That's a minor retreat from the 0.96% level that the prior note…
LLY short interest falls 25% in one week to 0.80% of float, lowest level since late July as bears continue rapid exit.
A new long-form analysis for LLY this week — anomalies vs the company's own history, peer comparisons, news context, and the full data picture. Premium subscribers only.
Read on ORTEX →Sign up for premiumEli Lilly and Company heads into the back half of September with the short rebuild that dominated last week's note showing its first real signs of fatigue — yet the broader story remains intact. Short interest slipped…
Snapshot as of 20 Sept 2026
Eli Lilly and Company heads into September with the most interesting tension not in the short book — which remains a non-story — but in a sharp shift in options sentiment and an analyst consensus that has kept lifting…
Eli Lilly and Company enters the back half of August with short sellers continuing to exit at pace — but Tuesday's 1% pullback to $1,233.66 comes on a week when close peer MRK surged 15.7%, making the comparison a…
Eli Lilly and Company has answered the question posed two weeks ago — $1,200 is a floor now, not a ceiling. The stock closed Tuesday at $1,225.73, up 3.6% on the day and nearly 1% on the week. That advance matters more…
Eli Lilly and Company has extended its post-earnings recovery into a second week, and the story is now less about the Q2 print itself and more about whether $1,200 becomes a new floor or a ceiling. The stock closed at…
Eli Lilly and Company reported Q2 earnings on August 5, and the defensive positioning that defined the prior three weeks of coverage has begun to dissolve — the question now is whether the stock's 8.6% weekly decline…
Eli Lilly and Company arrives at Wednesday's Q2 release with the stock having retreated from its all-time high, options hedging re-intensifying to the highest level of the past year, and short sellers holding their…
Eli Lilly and Company enters its August 5 Q2 print having added another 3.8% on the week to $1,220.66 — clearing the previous all-time high and leaving the defensive surge flagged two days ago looking slightly less…
Eli Lilly and Company has fallen a further 6.7% this week to $1,152.54, yet the analyst community has responded by raising targets — a widening gap between Street conviction and market price that defines this week's…
Eli Lilly and Company enters the back half of the week at $1,235.56, up 3% on the week, with a chorus of freshly raised analyst targets and an August 5 earnings date pulling focus. The Street's conviction is running…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for LLY — free to start on ORTEX.
Sign up for free →Open LLY on ORTEX